When was Aptorum Group founded?

Aptorum Group was founded in 2017 and raised its 1st funding round 5 years after it was founded.

Where is Aptorum Group located?

Aptorum Group is headquartered in London, United Kingdom.

How many employees does Aptorum Group have?

As of Jul 31, 2026, the latest employee count at Aptorum Group is 11.

Is Aptorum Group a funded company?

Aptorum Group is a funded company, having raised a total of $***** in its 1st and only funding round, a Post IPO round on Dec 09, 2022.

When was the latest funding round of Aptorum Group?

Aptorum Group's latest funding was a $***** Post IPO round on Dec 09, 2022, with participation from 1 investor.

Where does Aptorum Group rank among its competitors?

Aptorum Group ranks 1034th amongst 3994 active competitors, of which 1328 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Senti Bio, which secured $40M in May, 2026.

Who are the top competitors of Aptorum Group?

Aptorum Group's top competitors include Jazz Pharmaceuticals, BeiGene and Biogen. Among them, Senti Bio secured the most recent funding round in May, 2026.

Aptorum Group - 2026 Company Profile, Team, Funding, Competitors & Financials

Aptorum Group is a public company based in London (United Kingdom), founded in 2017 by Ian Huen. It operates as a Developer of small molecular therapeutics for multiple disorders. Aptorum Group has raised an undisclosed amount in funding. The company has 3994 active competitors, including 1328 funded and 926 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, BeiGene and Biogen.

Company Details

Developer of small molecular therapeutics for multiple disorders. The company's drug candidates include SACT-1 for neuroblastoma, ALS-4 for staphylococcus infection, ALS-1 for influenza, ALS-2 for bacterial infection, NLS-1 for endometriosis, and others.

Website: aptorumgroup.com
Social
Email ID: *****@aptorumgroup.com
Phone Number: +44 **********

Key Metrics

Founded Year

2017

Location

London, United Kingdom

Stage

Public

Latest Funding Round

Post IPO, Dec 09, 2022, $*****

Investors

Aenco

Ranked

1034^th among 3994 active competitors

Employee Count

11 as on Jul 31, 2026

Similar Companies

Jazz Pharmaceuticals & 3846 more

Exit Details

Public

View Aptorum Group's full profile

Aptorum Group is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
APTORUM GROUP LIMITED CIN: 11276209 , United Kingdom, Active	Dec 31, 2016	-	1 (As on Dec 31, 2024)

Aptorum Group got listed on Dec 18, 2018.

Click here to take a look at Aptorum Group's IPO in detail

Aptorum Group has raised funding over 1 round. Its latest funding round was a Post IPO round on Dec 09, 2022 for $*****. 1 investor participated in its latest round. Aptorum Group has 1 institutional investor.

Here is the list of recent funding rounds of Aptorum Group:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Dec 09, 2022	6376405	Post IPO	9810696	6874250	1948578	9080392

Access funding benchmarks and valuations. Sign up today!

View details of Aptorum Group's funding rounds and investors

The founders of Aptorum Group is Ian Huen. Ian Huen is the CEO of Aptorum Group.

Here are the details of Aptorum Group's key team members:

Ian Huen: Founder & CEO of Aptorum Group.
Contact Info: 1 email address

View details of Aptorum Group's Founder profiles and Board Members

Aptorum Group's employee count trend

Aptorum Group has 11 employees as of Jul 26. Here is Aptorum Group's employee count trend over the years:

Uncover Aptorum Group's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Aptorum Group include Jazz Pharmaceuticals, BeiGene and Biogen. Here is the list of Top 10 competitors of Aptorum Group, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	82/100
2nd	BeiGene 2010, Cambridge (United States), Public	Developer of targeted and immune-oncology drugs against cancer	$172M	Hillhouse, Boxer Capital & 13 others	80/100
3rd	Biogen 1978, Cambridge (United States), Public	Developer of therapies for neurodegenerative and immunology disorders	$80M	Berkshire Hathaway, Digital Pharma Lab & 11 others	78/100
4th	PTC Therapeutics 1998, South Plainfield (United States), Public	Developer of small molecule drugs for the treatment of rare diseases	$248M	HBM Healthcare Investments, Credit Suisse First Boston ... & 28 others	77/100
5th	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, F-Prime Capital & 17 others	73/100
6th	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Boxer Capital & 15 others	73/100
7th	Senti Bio 2016, San Francisco (United States), Public	Developer of cell and gene therapies for patients living with incurable diseases	$158M	Celadon Partners, New Enterprise Associates ... & 30 others	72/100
8th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
9th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Domain Associates, Fidelity Investments & 19 others	72/100
10th	Moderna 2010, Cambridge (United States), Public	Developer of mRNA-based therapeutics for a wide range of diseases	$2.78B	Merck, AstraZeneca & 32 others	71/100
1034th	Aptorum Group 2017, London (United Kingdom), Public	Developer of small molecular therapeutics for multiple disorders	-	Aenco	43/100